BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.05%. A quarter ago, it was expected that this rare disease drug developer would post a loss of $0.86 per share when it actually produced a loss of $1.08, delivering a surprise of -25.58%.Over the last four quarters, th ...